Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.
Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to treatment with aminoglutethimide plus cortisone acetate. All had relapsed from or failed to respond to primary endocrine treatment with orchidectomy or stilboestrol. Nineteen patients (48%) showed subjective response, in most cases relief of bone pain. Side effects limited treatment in only 3 patients. We conclude that aminoglutethimide plus cortisone acetate is a useful addition to the treatment available for this difficult group of patients. The mechanism by which this treatment has a beneficial effect remains unclear.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D000735:Androstenedione / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003348:Cortisone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000097:blood; D013196:Dihydrotestosterone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012894:Sleep Stages; D013739:Testosterone / Q000097:blood
D013196:Dihydrotestosterone; D000616:Aminoglutethimide; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D003348:Cortisone